The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Clinical trial updates and time-limited therapy in CLL
In this video, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses trials being conducted in frontline chronic lymphocytic leukemia (CLL) with time-limited therapy. Dr Jain highlights some of the results from the CLL14 trial (NCT02242942) investigating the use of venetoclax plus obinutuzumab, and briefly mentions the CAPTIVATE trial (NCT02910583), investigating the use of ibrutinib plus venetoclax in CLL. Following this, Dr Jain discusses the benefit of triplet combinations and the need to obtain long-term follow-up data from Phase III trials to choose the best regimens when treating patients. This interview was recorded virtually.
